Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...

which is in a phase 3 trial as a treatment for IgG4-related disease (IgG4-RD), phase 2/3 in warm autoimmune haemolytic anaemia (wAIHA), and phase 2 in multiple sclerosis (MS) and systemic lupus ...

MULTIPLE MYELOMA (MM), an incurable blood cancer, remains a major challenge in oncology, with a pressing need for novel treatment strategies. A new study has identified a significant metabolic ...

A GROUNDBREAKING study has uncovered key insights into the differing tumour rejection behaviours of chimeric antigen receptor T cells (CAR-T) targeting CD19, potentially paving the way for improved ...

In December, Nurix announced plans to initiate clinical testing of NX-5948 in autoimmune cytopenias, such as warm autoimmune hemolytic anemia (wAIHA), in 2025, initially as an addition to its ...